Know Cancer

forgot password

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

Phase 2
18 Years
90 Years
Not Enrolling
Prostatic Neoplasms, Prostate Cancer

Thank you

Trial Information

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

In summary, in vitro and in vivo studies, as well as early phase clinical trial, have shown
a promising role for both calcitriol and NSAIDs in the treatment of prostate cancer.
Moreover, calcitriol and NSAIDs both exert their antiproliferative effect by decreasing
prostaglandin levels, but they do so by different mechanisms. Thus, there is reason to
believe that their combined effects on prostaglandins may be synergistic. Preliminary in
vitro assays in which calcitriol is given in combination with one of two different NSAIDs
(Naprosyn or sulindac) to LNCaP cell lines have indicated such synergy. This observation
provides the rational for using them in combination for the treatment of prostate cancer. In
addition, it is hoped that any synergy noted would allow for the use of lower doses of

Inclusion Criteria:

- Must give written informed consent

- Histologically confirmed adenocarcinoma of the prostate

- Biochemical relapse after primary radiation therapy or surgery

- Normal testosterone levels

- 3 rising PSA after nadir, with interval between PSA determinations > 2 weeks

Exclusion Criteria:

- Local recurrence by CT scan

- Distant metastases by bone scan

- Hypercalcemia

- Nephrolithiasis

- Renal insufficiency (serum creatinine > 1.8 mg/dl)

- Pancreatitis

- History of ulcer or gastrointestinal bleeding

- More than 6 months of hormone ablation therapy

- Concurrent therapy for prostate cancer

- Uncontrolled HTN


- Known coronary disease/cerebrovascular disease

- Platelet counts <50

- Patients on anticoagulants

- Patients on lithium

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

PSA response - 50% PSA decline, PSA progression, PSA response duration, progressive disease, time to PSA progression.

Outcome Time Frame:


Safety Issue:


Principal Investigator

Dr. Sandy Srinivas

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University


United States: Institutional Review Board

Study ID:




Start Date:

March 2005

Completion Date:

July 2007

Related Keywords:

  • Prostatic Neoplasms
  • Prostate Cancer
  • Neoplasms
  • Prostatic Neoplasms



Stanford University School of MedicineStanford, California  94305-5317